{{--
  Back to User
--}}
{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
Back

A survey to assess the usage pattern of FDC of Paroxetine and clonazepam in the management of comorbid anxiety and depression in India

Survey Questionnaire Form
Doctor’s details
@if(isset(session()->get('doctor')['vCentralCode']))
@else
@endif

Questionnaire

  1. How many patients of comorbid depression and anxiety do you see in a month? *

  2. From your clinical experience, mention the most common symptoms patients present to you at diagnosis? *

  3. Do you consider FDC of Paroxetine and clonazepam as a first-line treatment for comorbid depression and anxiety? *

  4. What percentage of your comorbid depression and anxiety patients are currently prescribed FDC of Paroxetine and clonazepam? *

  5. In your experience, how effective do you find FDC of Paroxetine and clonazepam in managing comorbid depression and anxiety symptoms? *

  6. On a scale of 1 to 5, How satisfied are you with the current dosing options available for FDC of Paroxetine and clonazepam? (5 being very satisfied) *

  7. In your experience, how quickly do patients typically respond to FDC of Paroxetine and clonazepam treatment? *

  8. Which factors are critical for choosing FDC of Paroxetine and clonazepam in comorbid depression and anxiety? *

  9. How often do you adjust the dosage of FDC of Paroxetine and clonazepam for optimal symptom management? *

  10. On average, how long do your patients remain on FDC of Paroxetine and clonazepam treatment? *

  11. What is your typical starting dose of this formulation in comorbid anxiety and depression patients? *

  12. Do you prefer prescribing the fixed dose combination over giving paroxetine and clonazepam separately? (If not, please specify the reason.) *

  13. In your experience, does FDC of Paroxetine and clonazepam provide long-term benefits for comorbid anxiety and depression patients? *

  14. Have you observed any differences in treatment response based on patient’s age when prescribing FDC of Paroxetine and clonazepam in comorbid anxiety and depression patients? *

  15. Have you observed any differences in treatment response based on patient’s gender when prescribing FDC of Paroxetine and clonazepam in comorbid anxiety and depression patients? *

  16. What percentage of your patients report satisfactory compliance with FDC of Paroxetine and clonazepam treatment? *

  17. How do you typically monitor the effectiveness of FDC of Paroxetine and clonazepam treatment in your patients? *

  18. How satisfied are your patients with the response of the FDC of Paroxetine and clonazepam in managing their comorbid anxiety and depression patients? (5 being very satisfied) *

  19. How satisfied are your patients with the tolerability of the FDC of Paroxetine and clonazepam in managing their comorbid anxiety and depression patients? (5 being very satisfied) *

  20. Do you find FDC of Paroxetine and clonazepam more effective than other medications commonly prescribed for comorbid anxiety and depression patients? *

  21. What percentage of adult patients are exhibiting satisfactory tolerance with FDC of Paroxetine and clonazepam? *

  22. How do you assess the long-term efficacy of the FDC of Paroxetine and clonazepam in managing comorbid anxiety and depression patients? *

  23. What percentage of your comorbid anxiety and depression patients experience significant improvement in quality of life with FDC of Paroxetine and clonazepam? *

  24. In your experience, do patients with comorbid anxiety and depression having comorbidities influence your decision to prescribe FDC of Paroxetine and clonazepam and Why? *

  25. Based on your experience, do you think additional research is needed to better understand FDC of Paroxetine and clonazepam in comorbid anxiety and depression management? *

  26. In your opinion, what advantage does FDC of Paroxetine and clonazepam offer over other drugs in comorbid anxiety and depression management? *

  27. How would you rate your overall experience with prescribing FDC of Paroxetine and clonazepam in comorbid anxiety and depression management? (5 being very satisfied) *

  28. How do you adjust the treatment plan based on the disease progression? *